104741-23-3

Usage

Uses

Used in Pharmaceutical Synthesis:
1-((4-methoxy-3-nitrophenyl)sulfonyl)piperidine is used as an intermediate in the synthesis of various pharmaceuticals for its unique structural properties and potential biological activities.
Used in Agrochemical Synthesis:
1-((4-methoxy-3-nitrophenyl)sulfonyl)piperidine is also used as a building block in the development of agrochemicals, contributing to the creation of compounds with specific pesticidal or herbicidal properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-((4-methoxy-3-nitrophenyl)sulfonyl)piperidine is used as a compound of interest for studying its anti-inflammatory and analgesic properties, with the aim of developing new therapeutic applications.
Used in Drug Development:
Due to its potential biological activities, 1-((4-methoxy-3-nitrophenyl)sulfonyl)piperidine is utilized in drug development to create new medications that may have applications in treating various health conditions.

Upstream product

• 124-41-4 sodium methylate 
• 53162-43-9 1-(4-chloro-3-nitro-benzenesulfonyl)-piperidine 
• 110-89-4 piperidine 
• 97-08-5 3-nitro-4-chlorosulfonyl chloride 
• 98-68-0 4-methoxy-phenyl-sulphonyl chloride 
• 22117-79-9 4-methoxy-3-nitrobenzene-1-sulfonyl chloride 

Relevant academic research and scientific papers

4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines

Various malignant human diseases show disturbed signaling pathways due to increased activity of proteins within the epigenetic machinery. Recently, various novel inhibitors for epigenetic regulation have been introduced which promise a great therapeutic benefit. Inhibitors for the bromo- and extra-terminal domain (BET) family were of particular interest after inhibitors had shown a strong antiproliferative effect. More recently, the focus has increasingly shifted to bromodomains (BDs) outside the BET family. Based on previously developed inhibitors, we have optimized a small series of 4-acyl pyrroles, which we further analyzed by ITC, X-ray crystallography, selectivity studies, the NCI60 cell-panel, and GI50 determinations for several cancer cell lines. The inhibitors address both, BET and BRD7/9 BDs, with very high affinity and show a strong antiproliferative effect on various cancer cell lines that could not be observed for BD family selective inhibitors. Furthermore, a synergistic effect on breast cancer (MCF-7) and melanoma (SK-MEL-5) was proven.